Commentary

Treating depression, chronic pain


 

We read with interest Dr. Nelson’s and Dr. Krahn’s article on treating chronic pain and comorbid major depression (Current Psychiatry, May 2004).

We treat many patients who present with depression and chronic pain—often as a partial cause of their depression. The article’s recommendations will be most useful.

We have found that two agents—lamotrigine and mirtazapine—have been particularly helpful. The authors, however, did not mention these agents or only briefly referred to them.

Lamotrigine, although not FDA-approved for these uses, has demonstrated efficacy in unipolar depression1 and chronic pain.2 Although the medication has not been studied for treating comorbid depression and chronic pain, we can attest to its usefulness for such patients.

Mirtazapine is FDA-approved for depression and has been compared favorably with selective serotonin reuptake inhibitors3-4 or venlafaxine.5 Fewer data support using mirtazapine for chronic pain, but its sedating effects make it an option for treating any syndrome associated with sleep disturbance—ie, major depression and chronic pain.

Vida Robertson, MD
Michael S. Wilson, II, MD
Department of psychiatry
Louisiana State University Health Sciences Center
New Orleans

References

  1. Barbosa L, Berk M, Vorster M. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003;64(4):403–7.
  2. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology 2001;57(3):505–9.
  3. Winokur A. DeMartinis NA 3rd, McNally DP, et al. Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia. J Clin Psychiatry 2003;64(10):1224–9.
  4. Wade A, Crawford GM, Angus M, et al. A randomized, double-blind, 24-week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care. Int Clin Psychopharmacol 2003;18(3):133–41.
  5. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S; Mirtazapine-Venlafaxine Study Group. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001;21(4):425–31.

Recommended Reading

Persistent depression? Low libido? Androgen decline may be to blame
MDedge Psychiatry
Treating affective illness in patients with chronic pain
MDedge Psychiatry
Premenstrual moods or depression? Use logs to track monthly cycles
MDedge Psychiatry
Exercise and mood: Our parents were right
MDedge Psychiatry
SSRIs in pediatric patients
MDedge Psychiatry
NMS: Spelling it out
MDedge Psychiatry
On self-mutilation
MDedge Psychiatry
The painful truth about depression
MDedge Psychiatry
Exercise for depression: It really does help—here’s how to get patients moving
MDedge Psychiatry
Post-stroke depression: Rapid action helps restore lost function
MDedge Psychiatry